FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944717492> ?p ?o ?g. }

• W2944717492 endingPage "01" @default.
• W2944717492 startingPage "OT1" @default.
• W2944717492 abstract "Abstract Background: Annually, more than 4,000 patients are diagnosed with leptomeningeal carcinomatosis (LC) from breast cancer in the U.S. Since most therapies cannot cross the Blood-CSF-Barrier (BCB) and the Blood-Brain-Barrier (BBB), treatment options for LC are limited to local radiation and few chemotherapy agents, none of which have provided durable clinical benefit, leading to short overall survival (OS) of 3-4 months. ANG1005 is a novel peptide-drug conjugate, consisting of 3 paclitaxel molecules covalently linked to a peptide that targets the LRP-1 receptor to cross both BCB and BBB, and enter the tumor cells, where the paclitaxel is cleaved off to exert its anti-tumor activity. ANG1005 has previously shown in a phase 2 study to prolong OS in LC patients from breast cancer with brain metastases (BM) to 8 months. Trial Design: This is an open-label, multi-center phase 3 randomized study to evaluate the efficacy of ANG1005 in HER2-negative breast cancer patients with newly diagnosed LC and documented history of previously treated BM when compared to Physician Best Choice (PBC). Hundred and fifty (150) patients will be randomized 1:1 to receive either ANG1005 experimental treatment or an Investigator assigned PBC control treatment. ANG1005 will be administered by intravenous (IV) infusion at a starting dose of 600 mg/m2 every 3 weeks. Allowed PBC therapies include capecitabine, eribulin, or high-dose IV methotrexate. CNS disease (LC and BM) will be evaluated at screening and every 6 weeks by MRI, CSF cytology and neurological assessments according to LANO and RANO-BM criteria. Extracranial disease will be evaluated by CT scans according to RECIST at screening and every 6-12 weeks. All patients will be followed for survival every 6-8 weeks from the date of the last dose until death, lost to follow-up or consent withdrawal. Eligibility Criteria: Eligible patients are adults (≥ 18 years old) with HER2-negative breast cancer, newly diagnosed LC and documented history of previously treated BM. Patients must be neurologically stable and have adequate blood counts, organ and bone marrow function with an ECOG status grade ≤2. Patients previously treated with ANG1005 or with known allergy to paclitaxel or its components are excluded. Specific aims: The primary endpoint is OS. Secondary endpoints include CNS (LC and BM) progression-free survival and clinical benefit rate, 6- and 12-month OS rates, LC response rate and duration of response, OS for triple negative patients and safety. Statistical Methods: This study is sized for testing the hypothesis of improved OS for ANG1005 versus PBC in all patients (HR=0.58, two-sided test, overall type 1 error of 5%). Interim analysis for OS (using O'Brien Fleming boundaries for efficacy and a fixed HR=1 for futility) will be performed when a total of 55 death events are reached across both arms. Study Accrual: Target accrual is 150 patients. The study is currently planned to start in the fall of 2018. Citation Format: Kumthekar P, Lawrence B, Iordanova V, Ibrahim N, Mazanet R. ANG1005 in leptomeningeal disease (ANGLeD) trial: A randomized, open-label, phase 3 study of ANG1005 compared with Physician's Best Choice in HER2-negative breast cancer patients with newly diagnosed leptomeningeal carcinomatosis and previously treated brain metastases [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT1-06-01." @default.
• W2944717492 created "2019-05-16" @default.
• W2944717492 creator A5059764281 @default.
• W2944717492 creator A5072148862 @default.
• W2944717492 creator A5074108995 @default.
• W2944717492 creator A5075203244 @default.
• W2944717492 creator A5091750059 @default.
• W2944717492 date "2019-02-15" @default.
• W2944717492 modified "2023-09-27" @default.
• W2944717492 title "Abstract OT1-06-01: ANG1005 in leptomeningeal disease (ANGLeD) trial: A randomized, open-label, phase 3 study of ANG1005 compared with Physician's Best Choice in HER2-negative breast cancer patients with newly diagnosed leptomeningeal carcinomatosis and previously treated brain metastases" @default.
• W2944717492 doi "https://doi.org/10.1158/1538-7445.sabcs18-ot1-06-01" @default.
• W2944717492 hasPublicationYear "2019" @default.
• W2944717492 type Work @default.
• W2944717492 sameAs 2944717492 @default.
• W2944717492 citedByCount "2" @default.
• W2944717492 countsByYear W29447174922020 @default.
• W2944717492 countsByYear W29447174922021 @default.
• W2944717492 crossrefType "journal-article" @default.
• W2944717492 hasAuthorship W2944717492A5059764281 @default.
• W2944717492 hasAuthorship W2944717492A5072148862 @default.
• W2944717492 hasAuthorship W2944717492A5074108995 @default.
• W2944717492 hasAuthorship W2944717492A5075203244 @default.
• W2944717492 hasAuthorship W2944717492A5091750059 @default.
• W2944717492 hasConcept C121608353 @default.
• W2944717492 hasConcept C126322002 @default.
• W2944717492 hasConcept C141071460 @default.
• W2944717492 hasConcept C143998085 @default.
• W2944717492 hasConcept C2775930923 @default.
• W2944717492 hasConcept C2776387010 @default.
• W2944717492 hasConcept C2776694085 @default.
• W2944717492 hasConcept C2777909004 @default.
• W2944717492 hasConcept C31760486 @default.
• W2944717492 hasConcept C526805850 @default.
• W2944717492 hasConcept C530470458 @default.
• W2944717492 hasConcept C71924100 @default.
• W2944717492 hasConcept C90924648 @default.
• W2944717492 hasConceptScore W2944717492C121608353 @default.
• W2944717492 hasConceptScore W2944717492C126322002 @default.
• W2944717492 hasConceptScore W2944717492C141071460 @default.
• W2944717492 hasConceptScore W2944717492C143998085 @default.
• W2944717492 hasConceptScore W2944717492C2775930923 @default.
• W2944717492 hasConceptScore W2944717492C2776387010 @default.
• W2944717492 hasConceptScore W2944717492C2776694085 @default.
• W2944717492 hasConceptScore W2944717492C2777909004 @default.
• W2944717492 hasConceptScore W2944717492C31760486 @default.
• W2944717492 hasConceptScore W2944717492C526805850 @default.
• W2944717492 hasConceptScore W2944717492C530470458 @default.
• W2944717492 hasConceptScore W2944717492C71924100 @default.
• W2944717492 hasConceptScore W2944717492C90924648 @default.
• W2944717492 hasIssue "4_Supplement" @default.
• W2944717492 hasLocation W29447174921 @default.
• W2944717492 hasOpenAccess W2944717492 @default.
• W2944717492 hasPrimaryLocation W29447174921 @default.
• W2944717492 hasRelatedWork W2196426442 @default.
• W2944717492 hasRelatedWork W2796100748 @default.
• W2944717492 hasRelatedWork W2978552006 @default.
• W2944717492 hasRelatedWork W3031563781 @default.
• W2944717492 hasRelatedWork W3068005188 @default.
• W2944717492 hasRelatedWork W4205733538 @default.
• W2944717492 hasRelatedWork W4205779066 @default.
• W2944717492 hasRelatedWork W4233763500 @default.
• W2944717492 hasRelatedWork W4254679361 @default.
• W2944717492 hasRelatedWork W3129921008 @default.
• W2944717492 hasVolume "79" @default.
• W2944717492 isParatext "false" @default.
• W2944717492 isRetracted "false" @default.
• W2944717492 magId "2944717492" @default.
• W2944717492 workType "article" @default.